CSPC PHARMA: NEXT DAY DISCLOSURE RETURN
May 3 16:24
CSPC PHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2024
May 2 17:11
CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Apr 26 16:31
CSPC PHARMA: NOTIFICATION LETTER TO NON-REGISTERED HOLDER AND REQUEST FORM
Apr 25 22:25
CSPC PHARMA: NOTIFICATION LETTER TO SHAREHOLDER AND CHANGE REQUEST FORM
Apr 25 22:25
CSPC PHARMA: LETTER TO NEW REGISTERED SHAREHOLDERS AND REPLY FORM
Apr 25 22:24
CSPC PHARMA: PROXY FORM FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON 28 MAY 2024 AT 10:00 A.M. (AND AT ANY ADJOURNMENT THEREOF)
Apr 25 22:23
CSPC PHARMA: 2023 Environmental, Social and Governance Report
Apr 25 22:20
CSPC PHARMA: NEXT DAY DISCLOSURES RETURNS
Apr 22 18:17
CSPC PHARMA: NEXT DAY DISCLOSURES RETURNS
Apr 19 17:51
CSPC PHARMA: NEXT DAY DISCLOSURES RETURNS
Apr 18 17:45
CSPC PHARMA: NEXT DAY DISCLOSURES RETURNS
Apr 17 18:22
CSPC PHARMA: NEXT DAY DISCLOSURES RETURNS
Apr 16 17:59
CSPC PHARMA: NEXT DAY DISCLOSURES RETURNS
Apr 15 17:28
CSPC PHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024
Apr 2 17:38
CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - SEMAGLUTIDE INJECTION FOR OVERWEIGHT/OBESITY INDICATION OBTAINS CLINICAL TRIAL APPROVAL
Mar 25 17:07
CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - DAPAGLIFLOZIN TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Mar 22 16:31
CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6023 OBTAINS CLINICAL TRIAL APPROVAL
Mar 20 17:25
CSPC PHARMA: CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER
Mar 20 17:22
CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039)OBTAINS CLINICAL TRIAL APPROVAL
Mar 18 18:08
No Data
No Data